{"disease":{"id":"neoplasms-cancer-tumors","name":"neoplasms cancer tumors"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06805812","title":"Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study","phase":"","overall_status":"RECRUITING","enrollment_count":3500,"lead_sponsor_name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","has_results":false},{"nct_id":"NCT02568267","title":"Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":534,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT07030569","title":"RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","has_results":false},{"nct_id":"NCT03219268","title":"A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":277,"lead_sponsor_name":"MacroGenics","has_results":false},{"nct_id":"NCT07460570","title":"Nurse-Led Culturally Adapted Palliative and End-of-Life Training for Oncology Nurses in Oman","phase":"NA","overall_status":"COMPLETED","enrollment_count":189,"lead_sponsor_name":"Sultan Qaboos University","has_results":false},{"nct_id":"NCT04028479","title":"The Registry of Oncology Outcomes Associated With Testing and Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":167,"lead_sponsor_name":"Taproot Health","has_results":false},{"nct_id":"NCT05699135","title":"A Study to Learn About the Effect of Avelumab First-Line Maintenance in Canadian People With Advanced Bladder Cancer","phase":"","overall_status":"TERMINATED","enrollment_count":150,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT07038369","title":"A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":134,"lead_sponsor_name":"Atavistik Bio, Inc","has_results":false},{"nct_id":"NCT06903390","title":"Investigation of the Effect of Information on the Empowerment of Cancer Patients Using Question Prompt List: A Mixed Method Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":96,"lead_sponsor_name":"Marmara University","has_results":false},{"nct_id":"NCT03597581","title":"A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":89,"lead_sponsor_name":"Inspirna, Inc.","has_results":false},{"nct_id":"NCT07445243","title":"Integrated Chinese and Western Therapy for Cancer-Related Fatigue","phase":"NA","overall_status":"COMPLETED","enrollment_count":86,"lead_sponsor_name":"Taichung Tzu Chi Hospital","has_results":false},{"nct_id":"NCT02334722","title":"1 Week Versus 6 Weeks of Levetiracetam in Surgical Brain Tumor Patients","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":81,"lead_sponsor_name":"University of Florida","has_results":true},{"nct_id":"NCT00807859","title":"Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":65,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT04660929","title":"CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":48,"lead_sponsor_name":"Carisma Therapeutics Inc","has_results":false},{"nct_id":"NCT01730118","title":"Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT07582666","title":"Identifying and Mobilizing Personal Resources to Improve Well-Being in Cancer Participants Using the CAERES Protocol","phase":"NA","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"UniDistance Suisse","has_results":false},{"nct_id":"NCT06242119","title":"Clinical Application of the J-PET Scanner Prototype","phase":"","overall_status":"RECRUITING","enrollment_count":25,"lead_sponsor_name":"Jagiellonian University","has_results":false},{"nct_id":"NCT02943733","title":"Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":18,"lead_sponsor_name":"University of Wisconsin, Madison","has_results":false},{"nct_id":"NCT04166383","title":"VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":14,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02017509","title":"Immunoscore in Rectal Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":3,"lead_sponsor_name":"Providence Health & Services","has_results":false}],"total":20},"guidelines":[],"source":"Drug Landscape verified database"}